Skip to content

Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism

Optimal Hydrochlorothiazide Cessation in Diagnosis of Hyperparathyroidism

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02591160
Enrollment
2
Registered
2015-10-29
Start date
2015-05-31
Completion date
2017-09-13
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperparathyroidism

Brief summary

Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the ambulatory setting. PHPT may be cured with surgery and indications for intervention have been defined and include urinary calcium/creatinine clearance. Hydrochlorothiazide (HCTZ), the most commonly prescribed medication for hypertension, reduces urinary calcium excretion and confounds urinary testing. As a result, it is universally recommended that thiazide diuretics be stopped in advance of urinary testing. To date, no studies are available to provide evidence-based guidance as to how long HCTZ must be held for urinary calcium excretion to return to steady state in PHPT. The objective of this study is to serially calculate urinary calcium/creatinine clearance ration in patients with suspected PHPT while holding HCTZ to determine the minimum duration of medication cessation necessary for urinary calcium clearance to reach steady state.

Detailed description

In this study, adult patients will submit serum and 24 hour urine samples prior to HCTZ cessation and at the following intervals after cessation: 4-6 days, 14-16 days, 28-30 days, adn 90-92 days. To minimize confounding variable, patients will take supplemental Vitamin D and Calcium, monitor their daily calcium intake, and monitor blood pressure weekly. Alternative, non-diuretic, antihypertensive medication(s) may be prescribed at the discretion of the enrolling provider.

Interventions

PROCEDUREHCTZ cessation

Patients will stop taking their HCTZ for 3 months

Sponsors

University of Missouri-Columbia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Elevated calcium on at least two separate draws with coexistent elevated parathyroid hormone (PTH) on at least one occasion. 2. Taking Hydrochlorothiazide for hypertension 3. Following a wash period, patients must have a normal range 25-hydroxy Vitamin D level, thyroid stimulation hormone (TSH) and serum magnesium levels. 4. Controlled blood pressure 5. Willingness to comply with serial sampling 6. English as the primary language 7. Adults 18 years and older

Exclusion criteria

1. Unable to cease Hydrochlorothiazide for any reason 2. Congestive heart failure 3. Renal insufficiency (GFR \<60) 4. Cardiovascular event in the last 3 months - include myocardial infarction, new onset atrial fibrillation, and new onset bundle branch block 5. Take lithium or other diuretic medication in last 3 months 6. Positive family history of familial hypocalciuric hypercalcemia (FHH)

Design outcomes

Primary

MeasureTime frameDescription
Number of days for Calcium/Creatinine Clearance to normalize after stopping HCTZ2-3 yearsDetermination of the HCTZ cessation window

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026